bioMerieux SA · EURONEXT:BIM
bioMerieux SA — Investor Presentation (2007)
34 slides from bioMerieux SA's investor presentation, 2007
Slide 1: 2007-2012 Strategy
BIOME|IRIEUX 2007-2012 Strategy
Slide 2: Disclaimer
Disclaimer This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial and competitive uncertainties in France or in other countries. Further i
Slide 3: Outline
Outline Introduction Business Environment bioMérieux Today Strategic Plan 2
Slide 4: Outline
Outline Introduction Business Environment bioMérieux Today Strategic Plan 3
Slide 5: The in vitro diagnostics market
The in vitro diagnostics market ` An attractive, steadily growing market Z 2006: ~€24bn ($30bn) Up approx. 5% a year Z Growing healthcare needs, aging population Z New technologies, new markers, etc. Z In vitro diagnostics: lower healthcare costs and better clinical decisions ` A global market ` Hig
Slide 6: An attractive business model
An attractive business model ` A lineup combining instruments, reagents, software and services Z Instruments: platforms for conducting diagnostic tests Z Reagents: biological consumables Z Operating software and expert systems (epidemiological survey or therapeutic advice) Z Services: to build custo
Slide 7: Synergistic technologies for detecting pathologies
Synergistic technologies for detecting pathologies Molecular Clinical TECHNOLOGIES Bacteriology Immunoassays chemistry* Hematology Hemostasis biology Segment size (€m) 2,300 1,800 8,700 9,100 1,200 1,200 Growth 3% - 4% 10% - 12% 3% - 4% 4% - 5% 3% - 4% 3% - 4% Competitive Low Average High High Avera
Slide 8: A promising market
A promising market ` Huge opportunities: Z Unmet medical needs in diagnostics Z New technologies, new markers, etc. Z Explosion in medical knowledge thanks to genome mapping ` Market ready to pay premium for high medical-value tests ` Bacteriology: Growth potential and a limited number of players `
Slide 9: A shifting environment
A shifting environment ` Stiff competition in “routine” immunoassays ` Convergence of clinical chemistry, immunoassay and hematology tests into single, high-throughput platforms ` Downward trend in prices: Z Of routine tests Z Of certain high medical-value tests as competition increases ` An increas
Slide 10: Outline
Outline Introduction Business Environment bioMérieux Today Strategic Plan 9
Slide 11: bioMérieux today
bioMérieux today ` A major player in the in vitro diagnostics market Z 2006 sales: €1,037m Z No. 8 worldwide ` A pure player with a broad international presence Z 83% of sales generated outside France ` Strong positions in high-growth segments ` Continuous flow of new products thanks to high-perform
Slide 12: 2006: sales by region
2006: sales by region Sales: €1,037m, of which 83% generated outside France North America: 26% EMEA*: 56% up 6.9% up 5% (8.3% excl. France) up 5.9% Latin America: 7% Asia-Pacific: 11% up 7.1% up 7.9% *EMEA: Europe, Middle East, Africa 11 Growth rates calculated at constant scope of consolidation and
Slide 13: 2006: sales by technology
2006: sales by technology ` Clinical applications: €894m up 5.1% 49% Z Bacteriology: €506m up 6.5% Z Immunoassays*: €302m up 1.4% Z Molecular biology: €40m up 45.9% 29% 14% 4% ` Industrial applications: 4% €143m up 11.5% €47m Bacteriology Immunoassays Industry Molecular biology Other *Includes the V
Slide 14: Our strengths
Our strengths ` Sales network: high quality, dense global coverage ` R&D: substantial investment over the long term ` Bacteriology: co-leadership ` Industrial applications: global leadership ` A profile that facilitates partnerships Z Only company in the industry with extensive skills in bacteriolog
Slide 15: An experienced management team
An experienced management team ` Executive Committee Z Stéphane Bancel CEO Z Thierry Bernard Global Commercial Operations Z Eric Bouvier Deputy General Manager - Support Functions Z Richard Ding Strategy, Business Development & Theragnostics Z Jean-Marc Durano Manufacturing & Quality Z Peter Kaspar
Slide 16: Challenges and pathways to improvement
Challenges and pathways to improvement ` VIDAS immunoassay range Z Leverage point-of-care position Z Competition in routine tests ` Improving new product time-to-market ` Optimizing information technologies Ö Productivity gains/customer solutions ` Continuously improving process engineering and prod
Slide 17: Outline
Outline Introduction Business Environment bioMérieux Today Strategic Plan 16
Slide 18: Strategic plan
Strategic plan Staying ahead of a changing market ` From a strategy focused on the laboratory Z Infectious diseases, oncology and cardiology Z Industrial applications ` To a strategy focused on pathologies and clinicians' needs Z Infectious agents: clinical and industrial applications Z Tests delive
Slide 19: Leveraging the quality of the sales network
Leveraging the quality of the sales network 2007-2012 growth rate* ` Internal R&D pipeline 5% - 6% ` Sales network optimization ~1% 185 385 413 316 604 France Latin America ROE Asia-Pacific North America Sales and Marketing: 1,903 FTE** 18 **Full-Time Equivalent; includes Customer Service *At consta
Slide 20: Optimizing the sales network
Optimizing the sales network ` Creation of a Global Commercial Operations Department Z Sales, marketing and customer service Z Vice President: Thierry Bernard, former Executive VP of EMEA ` Priority regions: United States and Japan Z Example: bacteriology market share › Europe : ~50% › US : ~30% › J
Slide 21: Leveraging the quality of the sales network
Leveraging the quality of the sales network 2007-2012 growth rate* ` Internal R&D pipeline 5% - 6% ` Sales network optimization ~1% ` Business development 185 385 1% - 2% 413 316 Z Distribution agreements Z Acquisitions: 604 › Product companies like Bacterial Barcodes › Etc. France Latin America ROE
Slide 22: Executing the acquisition strategy
Executing the acquisition strategy ` Business development: creation of a global department Cambridge Richard Ding Tokyo Marcy l’Etoile Shanghai ` Strengthening the team Z 3 new managers Z Expertise in business development and M&A ` Alain Mérieux and Stéphane Bancel personally involved 21
Slide 23: Leveraging the quality of the sales network
Leveraging the quality of the sales network 2007-2012 growth rate* ` Internal R&D pipeline 5% - 6% ` Sales network optimization ~1% ` Business development 185 385 1% - 2% 413 316 Z Distribution agreements Z Acquisitions: 604 › Product companies like Bacterial Barcodes › Etc. France Latin America ROE
Slide 24: Clinical applications
Clinical applications Be recognized by biologists and clinicians as a leader in key pathologies Bacteriology Molecular biology Immunoassays Infectious diseases • Sepsis BacT/ALERT GeneXpert VIDAS PCT • Hospital-acquired infections PPM, VITEK 2 Diversilab VIDAS CDA2 • Tuberculosis BacT/ALERT Gen-Prob
Slide 25: Bacteriology
Bacteriology Become the undisputed leader ` Objectives Z Drive complete automation of laboratories and analysis processes Z 2012: market share of approx. 40% ` Organic growth - R&D Z PPM: growth driven by chromogenic culture mediums 2004-06: >10%/year Z Identification and antibiogram (ID/AST): menu
Slide 26: Molecular biology
Molecular biology Become the leader in sepsis and hospital-acquired infections ` Objective Z 2012: increase market share from 2% to around 8% in infectious diseases ` Organic growth - R&D Z Expand the NucliSENS EasyQ platform menu: launch of EasyQ HPV - Q2 2007 Z Introduce a new, more automated plat
Slide 27: Immunoassays
Immunoassays Extend the high medical-value test menu and strengthen the point-of-care business ` Objectives Z VIDAS/VIDIA: strengthen the franchise Z Point-of-care: develop a manual and semi-automated range ` Organic growth - R&D Z VIDAS range: optimize the installed base with new high medical-value
Slide 28: Theragnostics
Theragnostics* Become a preferred partner for pharmaceutical and biotech companies ` Objectives Z Sign two agreements by end-2008 and approx. ten by end-2012 ` Applications Z Efficacy tests: identify patients who respond to treatment Z Side effects: identify patients for whom treatment would be harm
Slide 29: Industry
Industry Lead sector consolidation ` Objective Z 2012: market share of approx. 30% bioMérieux 3M / Biotrace BD Oxoid Merck AES Qualicon (Dupont) Millipore Bio-Rad Other A fragmented market* 28 * bioMérieux estimate
Slide 30: Industry
Industry Lead sector consolidation ` Objective Z 2012: market share of approx. 30% ` Organic growth - R&D Z PPM: growth driven by chromogenic culture media Z TEMPO: US launch in Q1 2007 and menu extension Z Molecular biology: first test for industry to be launched in 2007 ` External growth Z Distrib
Slide 31: Outlook
Outlook ` Sales Z 2007 - 2012: Compound annual growth rate of 7% - 9% at constant exchange rates: › R&D – current pipeline: 5% - 6% › Sales network optimization: ~1% › Acquisitions: 1% - 2% Z 2007: 6% - 7%, at constant exchange rates and scope of consolidation, excl. external growth ` Margins Z Stab
Slide 32: Clear objectives
Clear objectives ` A strategy focused on patients and pathologies Z Infectious agents: clinical and industrial applications Z High medical-value tests: oncology, cardiology, point-of-care and theragnostics ` A strategy that leverages our strengths Z Bacteriology: become the undisputed leader Z Indus
Slide 33: Growth drivers
Growth drivers ` Organic growth: supported by sustained R&D investment ` An optimized, enhanced sales network ` Acquisitions/distribution agreements: Z A global business development team, close to targets Z Ability to move fast and close quickly Z A reservoir of opportunities among private companies
Slide 34: Conclusion
Conclusion ` An attractive, steadily growing market ` A seamless strategy to stay ahead of a changing market ` An increasingly international player ` A company re-focused on its core strengths ` A solid track record Z More than 40 years of experience in infectious diseases Z Demonstrated innovation